/
Infectious Disease
HIV Infection
44
Pipeline Programs↗
29
Active Trials↗
29
Companies Involved↗
HIV infection is a moderately active landscape with 44 programs across 29 companies. The most active players are Code Pharma. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 13
Phase 26
Phase 311
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
32 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 86% of 44 pipeline programs.
Analysis
Trial Status
225
clinical trials
Completed155 · 69%
Unknown status17 · 8%
Terminated14 · 6%
Recruiting13 · 6%
Not yet recruiting8 · 4%
Active, not recruiting7 · 3%
Other11 · 5%
Clinical Trials
Trial Activity
225 trials
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02140255·1,120 enrolled
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05719441·48 enrolled
CAR-T Cells for HIV Infection
Recruiting·—·Phase 1/2·NCT04648046·18 enrolled
A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04340596·118 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)